Combined with the markedly reduced risk of IgE binding and anaphylaxis associated with the use of short peptides for immunotherapy, we believe that apitope immunotherapy would improve patient compliance with treatment and help slow the progression of diseases such as allergic rhinitis and asthma. The gene discussed is IGHE; the disease is asthma.